High dose therapy and autologous hematopoietic stem cell transplantation in septuagenarians with non-Hodgkin lymphoma: Feasible, but for which patients?

Wildes, Tanya M.; Cashen, Amanda F.

doi:10.1016/j.jgo.2015.07.001

Cited by 2 publications

(2 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Autologous stem cell transplantation has been recognized in the treatment of ischemic disease. Bone marrow mesenchymal stem cells (MSCs) are a rich source, easy to obtain, and have been safe in vitro amplification techniques, so are widely used in vascular tissue engineering [ 19 ]. Gładysz et al reported that MSCs play a therapeutic role in two ways after transplant to microvascular lesion.…”

Section: Discussionmentioning

confidence: 99%

Peroxisome Proliferator-Activated Receptor-γ Coactivator-1α (PGC-1α) Regulates the Expression of B-Cell Lymphoma/Leukemia-2 (Bcl-2) and Promotes the Survival of Mesenchymal Stem Cells (MSCs) via PGC-1α/ERRα Interaction in the Absence of Serum, Hypoxia, and High Glucose Conditions

et al. 2017

View full text Add to dashboard Cite

BackgroundTo study the effect of estrogen-related receptor α (ERRα) and peroxisome proliferator-activated receptor-γ coactivator-1α (PGC-1α) on mesenchymal stem cells (MSCs) apoptosis, and further investigated its detailed molecular mechanisms in the absence of serum, hypoxia, and high glucose conditions.Material/MethodsIn our study, we first evaluated the expression rates of CD14, CD34, CD45, CD44, CD29, and Sca-1 surface markers on MSCs by flow cytometry. Then, the ability of osteogenic and fatty differentiation of MSCs was determined by osteogenic differentiation and adipogenesis reagent kit. Next, Annexin V-APC/7-AAD apoptosis kit was used for detecting the apoptosis rate of MSCs. RT-PCR and Western blotting were used for detection of mRNA expression and proteins expression, respectively.ResultsOur data showed that the MSCs used in our study were capable of self-renewal and differentiating into many cell lineages, such as osteogenic differentiation and adipogenesis. Our results further showed that over-expression of PGC-1α could protect MSCs from apoptosis induced by rotenone. We also found that PGC-1α over-expression could enhance the expression of anti-apoptotic gene Bcl-2, and inhibit the expression of pro-apoptotic gene Bax in MSCs. In addition, our data demonstrated that PGC-1α could induce upregulation of Bcl-2 and further promote the survival of MSCs by interacting with ERRα.ConclusionsIn the absence of serum, hypoxia and high glucose conditions, PGC-1α can regulate the expression of Bcl-2 and promote the survival of MSCs via PGC-1α/ERRα interaction.

show abstract

Section: Discussionmentioning

confidence: 99%

Peroxisome Proliferator-Activated Receptor-γ Coactivator-1α (PGC-1α) Regulates the Expression of B-Cell Lymphoma/Leukemia-2 (Bcl-2) and Promotes the Survival of Mesenchymal Stem Cells (MSCs) via PGC-1α/ERRα Interaction in the Absence of Serum, Hypoxia, and High Glucose Conditions

et al. 2017

View full text Add to dashboard Cite

show abstract

“…NHL is the most common hematologic malignancy and the sixth cause of death from cancer in the USA [ 2 ]. High dose therapy (HDT) followed by autologous stem cell transplantation (ASCT) is a potentially curative therapeutic alternative for resistant or relapsed NHL patients [ 3 ]. Even for many cases of high risk NHL, the only potentially curative option is stem cell transplantation [ 4 ].…”

mentioning

confidence: 99%

Radioimmunotherapy-Based Conditioning Regimen Prior to Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma

Eskian

Khorasanizadeh

Isidori

et al. 2018

Int. J. Hematol. Oncol.

View full text Add to dashboard Cite

Non-Hodgkin lymphoma (NHL) is the most common hematologic malignancy and the sixth cause of death from cancer in the USA. Autologous stem cell transplantation (ASCT) is a potentially curative therapeutic option for many NHL patients. Choosing the most effective conditioning regimen prior to ASCT can lead to longer survival in these patients, and, as in many cases of high risk NHL, the only potentially curative option is stem cell transplantation. Radioimmunotherapy (RIT) is based on using radiolabeled monoclonal antibodies against tumoral antigens. Since lymphoma cells are sensitive to radiation, RIT has become a potential approach in treating NHL. In this review, we have discussed the efficacy and safety of RIT as an alternative conditioning regimen prior to ASCT.

show abstract

High dose therapy and autologous hematopoietic stem cell transplantation in septuagenarians with non-Hodgkin lymphoma: Feasible, but for which patients?

Abstract: Editorial will accompany Hermet et al. “Autologous hematopoietic stem cell transplantation in elderly patients (≥ 70 years) with non-Hodgkin’s lymphoma: a French Society of Bone Marrow Transplantation and Cellular Therapy retrospective study.”

Cited by 2 publications

References 11 publications

Peroxisome Proliferator-Activated Receptor-γ Coactivator-1α (PGC-1α) Regulates the Expression of B-Cell Lymphoma/Leukemia-2 (Bcl-2) and Promotes the Survival of Mesenchymal Stem Cells (MSCs) via PGC-1α/ERRα Interaction in the Absence of Serum, Hypoxia, and High Glucose Conditions

Peroxisome Proliferator-Activated Receptor-γ Coactivator-1α (PGC-1α) Regulates the Expression of B-Cell Lymphoma/Leukemia-2 (Bcl-2) and Promotes the Survival of Mesenchymal Stem Cells (MSCs) via PGC-1α/ERRα Interaction in the Absence of Serum, Hypoxia, and High Glucose Conditions

Radioimmunotherapy-Based Conditioning Regimen Prior to Autologous Stem Cell Transplantation in Non-Hodgkin Lymphoma

Contact Info

Product

Resources

About